Analysts Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) PT at $19.67

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has earned an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $19.67.

A number of equities analysts have recently weighed in on ALXO shares. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Wednesday, May 29th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a research note on Monday, June 10th.

ALX Oncology Stock Down 6.8 %

NASDAQ:ALXO opened at $5.45 on Friday. The stock’s fifty day simple moving average is $7.89 and its 200-day simple moving average is $12.03. The firm has a market capitalization of $283.95 million, a P/E ratio of -1.47 and a beta of 1.06. The company has a quick ratio of 5.21, a current ratio of 5.21 and a debt-to-equity ratio of 0.06. ALX Oncology has a 12-month low of $3.94 and a 12-month high of $17.83.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.16. Equities research analysts expect that ALX Oncology will post -2.89 earnings per share for the current year.

Insider Transactions at ALX Oncology

In other ALX Oncology news, insider Sophia Randolph sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $15.94, for a total value of $191,280.00. Following the sale, the insider now owns 330,349 shares in the company, valued at approximately $5,265,763.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $8.43, for a total value of $168,600.00. Following the completion of the transaction, the insider now owns 604,205 shares in the company, valued at approximately $5,093,448.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sophia Randolph sold 12,000 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $15.94, for a total value of $191,280.00. Following the transaction, the insider now directly owns 330,349 shares of the company’s stock, valued at $5,265,763.06. The disclosure for this sale can be found here. Insiders sold 78,469 shares of company stock valued at $873,346 over the last three months. Company insiders own 33.40% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in ALXO. Vestal Point Capital LP bought a new position in shares of ALX Oncology in the fourth quarter valued at $24,643,000. Redmile Group LLC increased its stake in shares of ALX Oncology by 18.2% during the 1st quarter. Redmile Group LLC now owns 4,326,509 shares of the company’s stock worth $48,241,000 after purchasing an additional 667,245 shares during the last quarter. TD Asset Management Inc bought a new stake in shares of ALX Oncology in the 4th quarter valued at about $1,048,000. abrdn plc acquired a new stake in ALX Oncology in the 4th quarter valued at about $986,000. Finally, Vanguard Group Inc. grew its holdings in ALX Oncology by 4.3% during the first quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock worth $17,466,000 after purchasing an additional 64,055 shares during the period. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.